Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

3 1 1

What is this study about?

This clinical trial is focused on studying treatments for patients with a type of cancer called gastric cancer or gastroesophageal junction cancer. These are cancers that occur in the stomach or where the stomach meets the esophagus. The study will explore the effects of a medication called Durvalumab, which is given as an infusion, meaning it is delivered directly into the bloodstream through a vein. Durvalumab is being tested in combination with a chemotherapy regimen known as FLOT, which includes the drugs Fluorouracil, Leucovorin (also known as Folinic Acid), Oxaliplatin, and Docetaxel. These drugs are used to kill cancer cells or stop them from growing. The study will also involve a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The purpose of this study is to see if the combination of Durvalumab and FLOT chemotherapy, followed by additional Durvalumab treatment, can improve outcomes for patients with resectable gastric or gastroesophageal junction cancer. “Resectable” means that the cancer can be surgically removed. The study will be conducted in phases, starting with treatment before surgery (neoadjuvant) and continuing after surgery (adjuvant). Participants will be randomly assigned to receive either the active treatment or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This is known as a double-blind study.

The study will last for a period of up to 18 months, during which participants will receive the treatments and be monitored for their health and response to the treatment. The main goal is to assess event-free survival, which means the length of time participants live without the cancer getting worse or coming back. Secondary goals include overall survival and the rate of complete response to the treatment. This study aims to provide valuable information on the effectiveness of Durvalumab in combination with FLOT chemotherapy for treating gastric and gastroesophageal junction cancers.

1 joining the study

Upon joining the study, the patient is confirmed to have a type of cancer called gastric or gastroesophageal junction adenocarcinoma that can be surgically removed.

The patient must not have received any previous treatment for this cancer and should have a good performance status as per the World Health Organization (WHO) or Eastern Cooperative Oncology Group (ECOG) scale.

2 neoadjuvant treatment phase

The patient receives a combination of medications before surgery, known as neoadjuvant treatment. This includes durvalumab administered intravenously, and a chemotherapy regimen called FLOT, which consists of fluorouracil, folinic acid, oxaliplatin, and docetaxel, all given intravenously.

The purpose of this phase is to shrink the tumor before surgical removal.

3 surgery

The patient undergoes surgery to remove the cancerous tissue. This is a critical step in the treatment process.

4 adjuvant treatment phase

After surgery, the patient receives additional treatment to eliminate any remaining cancer cells. This is known as adjuvant treatment.

The patient continues to receive durvalumab intravenously to help prevent cancer recurrence.

5 follow-up and monitoring

The patient is regularly monitored to assess the effectiveness of the treatment and to check for any signs of cancer returning.

This phase includes regular medical check-ups and imaging tests as needed.

Who Can Join the Study?

Patients must have a confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma. This means the cancer is in the stomach or where the stomach meets the esophagus, and it has been confirmed by examining tissue under a microscope.
The disease must be resectable, meaning it can be removed by surgery, and it should be at Stage II or higher according to the AJCC 8th edition, which is a system used to describe the extent of cancer.
Patients must have undergone radical surgery, which is a type of surgery aimed at removing all cancerous tissue.
No previous anti-cancer therapy should have been received for the current cancer. This means the patient should not have had treatments like chemotherapy or radiation for this cancer before.
Patients should have a World Health Organization (WHO)/ECOG Performance Status of 0 or 1 at enrollment. This is a scale that measures how well a patient can perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
Patients must have adequate organ and marrow function, meaning their organs and bone marrow are working well enough to handle the treatment.
A tumor sample must be available before entering the study. This is a piece of the cancer that has been removed and can be used for testing.
Patients must have a life expectancy of at least 24 weeks, meaning they are expected to live for at least 24 weeks.
Both male and female patients can participate.

Who Cannot Join the Study?

Patients with a type of stomach cancer called adenocarcinoma that is not at a stage where it can be surgically removed.
Patients with a type of cancer that is not located in the stomach or the area where the stomach meets the esophagus.
Patients who have a type of cancer that is not classified as Stage II or higher according to the AJCC 8th edition, which is a system used to describe the extent of cancer.
Patients who are not within the specified age range for the study.
Patients who are not part of the specified clinical trial groups.
Patients who are not male or female, as both genders are included in the study.
Patients who are considered part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Haematologisch Onkologische Praxis Eppendorf	Hamburg	Germany
University Hospital Jena KöR	Jena	Germany
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Universitaetsklinikum Heidelberg AöR	Heidelberg	Germany
Centre Hospitalier Regional Et Universitaire De Brest	Brest	France
Technische Universitaet Dresden	Dresden	Germany
Katholieke Universiteit te Leuven	Leuven	Belgium

Other Sites

Site Name	City	Country
Krankenhaus Nordwest GmbH	Frankfurt	Germany
Hopital Saint Antoine	Paris	France
Centre Antoine Lacassagne	Nice	France
Orszagos Onkologiai Intezet	Budapest	Hungary
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)	Munich	Germany
Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH	Schweinfurt	Germany
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Algemeen Ziekenhuis Delta	Roeselare	Belgium
Grand Hopital De Charleroi	Charleroi	Belgium
Wielkopolskie Centrum Onkologii Im. Marii Sklodowskiej-Curie	Poznan	Poland
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet	Szolnok	Hungary
Bialostockie Centrum Onkologii Im. Marii Sklodowskiej-Curie W Bialymstoku	Bialystok	Poland
Tolna Vármegyei Balassa János Kórház	Szekszard	Hungary
Virgen del Rocío University Hospital	Sevilla	Spain
Odense University Hospital	Odense	Denmark
Universitaetsklinikum Tuebingen AöR	Tuebingen	Germany
Charite Universitaetsmedizin Berlin KöR	Berlin	Germany
SLK-Kliniken Heilbronn GmbH	Heilbronn	Germany
Catharina Ziekenhuis Stichting	Eindhoven	The Netherlands
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy	Warsaw	Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie	Cracow	Poland
Aalborg University Hospital	Aalborg	Denmark
Centre Hospitalier Universitaire De Nantes	Nantes	France
CHC MontLegia	Liege	Belgium
Uniwersytecki Szpital Kliniczny W Poznaniu	Poznan	Poland
Centre Hospitalier Universitaire De Rennes	Rennes	France
Rigshospitalet	Copenhagen	Denmark
Netherlands Cancer Institute	Amsterdam	The Netherlands
Hopital Beaujon	Clichy	France
Institut Sainte Catherine	Avignon	France
Iahzobxy Rtqnpbsg Di Cjkjgg Dy Miyeqepvokf	Montpellier	France
Cjdgef Lfyl Brivsr	Lyon	France
Ulfgsypmxo Merxwaj Csmwrc Hbklucsbemejaxpca	Hamburg	Germany
Huxurstl Usqdhibckjdgb Msenldb De Vojtwhfkyg	Santander	Spain
Ieqkmfen Cbkpde Dfufaswepsxkojwdr	L'hospitalet De Llobregat	Spain
Wymuunyzqzm Wuofsbdabuxionpqubss Cfabtxm Oasjiypkj I Thipycrzijxen Il Myhnhkgwqvh W Luppj	Lodz	Poland
Byaqjriwial Vwxhtfmsb Ojosfkfqpasj	Kecskemet	Hungary
Cqazyk Holoylakksh Uemwufeqzjooz Dm Dfdnv	Dijon	France
Azselvhypi Padaqzkt Hgchbaao De Pyayh	Paris	France
Bcossadv Ueheewikpo Hrgnuqql Cgokre	Besançon	France
Exzjtpa Ukdxgypgyzsk Mtlhkck Cqktkbf Rafvkctjv (ablvvxu Mcq	Rotterdam	The Netherlands
Grdywadrpdmlhuokd Vekqhaerh Pcro Akaixm Evbljanv Ogomcr Kyvuko	Gyor	Hungary
Ntmvtfqs Ibkyqdyj Omujiipju Idd Mciip Sbtqkwrtnuaftwssggnuovyemxea Ikeqdkrd Bhcuihrb	Cracow	Poland
Uwgzktjgktxwig Cmubhmh Kfryprqbe	Gdansk	Poland
Hgyaeiwv Df Lh Sefay Ctmz I Sjge Per	Barcelona	Spain
Udsqntosqr Of Akmqwkm	Edegem	Belgium
Hjbtokuq Vkrf dhjhhsaq	Barcelona	Spain

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	08.12.2023
Denmark	Not recruiting	08.12.2023
France	Not recruiting	08.12.2023
Germany	Not recruiting	08.12.2023
Hungary	Not recruiting	08.12.2023
Poland	Not recruiting	08.12.2023
Spain	Not recruiting	08.12.2023
The Netherlands	Not recruiting	08.12.2023

Trial locations

Investigated drugs:

Durvalumab is a medication used in this clinical trial to help the body’s immune system fight cancer. It works by blocking a specific protein that can stop the immune system from attacking cancer cells. In this study, it is given to patients both before and after surgery to see if it can improve the chances of the cancer not coming back.

FLOT Chemotherapy is a combination of four different chemotherapy drugs used together to treat gastric and gastroesophageal junction cancer. This combination is used to shrink the tumor before surgery and to kill any remaining cancer cells after surgery. The goal is to improve the overall effectiveness of the treatment and increase the chances of a successful outcome.

Investigated diseases:

Gastric cancer

Gastric Adenocarcinoma – This is a type of cancer that begins in the glandular cells of the stomach lining. It typically progresses by invading the stomach wall and can spread to nearby lymph nodes and other organs. The disease is often categorized by stages, with Stage II or higher indicating more advanced disease. Symptoms may include abdominal pain, weight loss, and nausea. The progression can vary, with some cases remaining localized while others spread more extensively. Early detection is crucial for managing the disease effectively.

Gastroesophageal Junction Adenocarcinoma – This cancer occurs where the esophagus meets the stomach, known as the gastroesophageal junction. It develops from the glandular cells in this area and can progress by invading surrounding tissues and spreading to other parts of the body. The disease is staged similarly to gastric adenocarcinoma, with higher stages indicating more extensive disease. Common symptoms include difficulty swallowing, chest pain, and unintended weight loss. The progression can lead to complications if not addressed in a timely manner. Understanding the stage of the disease is important for determining the appropriate management approach.

Trial ID:

2023-507338-26-00

Protocol code:

D910GC00001

NCT ID:

NCT04592913

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?